The antiarrhythmic effect of oral captopril was studied during the early (day 3) and late (day 14) phase of acute myocardial infarction among 304 patients in a randomized placebo-controlled substudy of ISIS^t.
Introduction
The renin-angiotensin-aldosterone system is activated in the acute phase of myocardial infarction and this is associated with various complications including ventricular arrhythmias 1 ' 1 . It seems likely that this relationship is causal since activation of the reninangiotensin-aldosterone system increases systemic and coronary vascular resistance, which results in a rise in myocardial wall stress and a fall in coronary blood flow, augments urinary excretion of potassium and magnesium, and exerts a direct toxic effect on myocardial cells' logical properties of the heart leading to an increased propensity to arrhythmias' 451 . Angiotensin converting enzyme (ACE) inhibitor therapy has been reported to produce antiarrhythmic effects in patients with congestive heart failure 16 ' 71 , while in 11 patients with frequent ventricular ectopic beats and preserved left ventricular systolic function captopril was not shown to suppress ventricular ectopic activity 181 . Several small studies of the effects on ventricular arrhythmias of ACE inhibitor therapy during and after acute myocardial infarction have been published. In 1992, our group reported that captopril suppressed ventricular ectopic beats in the third week after myocardial infarction'
91
. In 1993, Pipilis et al. ll0] observed a non-significant reduction in the frequencies of idioventricular rhythm and in the number of ventricular ectopic beats per hour during the first 48 h after the start of treatment in acute myocardial infarction among 32 patients allocated captopril compared with those allocated placebo. More recently Di Pasquale et a/.'" 1 reported that captopril given before thrombolysis reduced the incidence of reperfusion arrhythmias, as well as of predischarge ventricular arrhythmias, as compared with those allocated captopril from the 3rd day of myocardial infarction. Similarly, in CATS' 121 the incidence of reperfusion arrhythmias was significantly reduced by giving captopril with thrombolytic therapy during the acute phase of myocardial infarction. Soogard et a/.
1 ' 31 did not observe an antiarrhythmic effect as a result of captopril administration on day 30 after myocardial infarction but in that study the drug was started on the 7th day after the onset of myocardial infarction. However, captopril induced a significant antiarrhythmic effect by 6 months, with a correlation between left ventricular dysfunction and arrhythmias.
It may be that any antiarrhythmic effects as a result of ACE inhibitor therapy are greatest when treatment is started early in acute myocardial infarction. To assess more reliably the effects on arrhythmias of the early use of ACE inhibitor therapy we prospectively planned a much larger Holter arrhythmia study than had previously been conducted among a subset of patients entering ISIS-4' 14 '.
Methods

Study group and treatment
ISIS-4 is described in detail elsewhere' 14 '. Patients were eligible if symptoms of suspected acute myocardial infarction had started within 24 h and there were no clear indications for, or contraindications to, oral ACE inhibitors, oral nitrates and intravenous magnesium, each of which was tested in ISIS^t. Randomization was performed by a central 24 h telephone randomization service. A 2 x 2 x 2 factorial study design was used, with half the patients randomly allocated to receive oral captopril (initial dose 625 mg, followed 2 h later by 12-5 mg, 12 h later by 25 mg, and then 50 mg twice daily) or matching placebo for 28 days. Apart from the trial medications, routine treatment was administered at the discretion of attending physicians.
Patients admitted to coronary care units at Grochowski Hospital in Warsaw and Dietla Hospital in Cracow between July 1991 and August 1993 with suspected acute myocardial infarction were considered for the arrhythmia substudy. This substudy was approved by the institutional ethical committees of both hospitals.
Recording and analysis of arrhythmias in the Holter substudy
Twenty-four hour Holter ambulatory monitoring was performed on day 3 ± 1 and day 14 ± 2 after admission to the CCU. Both recordings were available for reliable analysis from 304 of 469 randomized patients (the limited availability of Holter recorders prevented some patients from undergoing the monitoring). Arrhythmias were traced onto both MTM Multitechmed two channel recorders (Grochowski Hospital) and Oxford Medilog II single channel recorders (Dietla Hospital).
Replay-under-visual-control analysis was conducted by physicians unaware of the patients' allocated treatment regimen. The number of ventricular ectopic beats per hour of recording time, ventricular tachycardia (defined as a sequence of three or more ventricular ectopic beats at a heart rate >110/min) were recorded as were the presence of complex ventricular arrhythmias (multifocal ventricular ectopic beats, pairs and/or ventricular tachycardia).
Statistical analysis
Data are presented as means with standard deviations (SD) or percentages. Ventricular ectopic beats/hour are not normally distributed in patients with acute myocardial infarction, and so the values obtained were logarithmically transformed for statistical comparisons. Statistical analysis was performed using the SPSS/PC+ program. Variance analysis and Student unpaired t-test were used to compare the frequency of arrhythmias in the treatment groups. The incidence of ventricular arrhythmias as a categorical variable was also compared by the chi-square test. A P value <005 was considered significant.
Results
Patient characteristics
Baseline pre-randomization patient characteristics (Table 1) were well-balanced between the treatment groups. Patients were randomized at an average of 11 h from the onset of symptoms of suspected acute myocardial infarction. ST segment elevation of the initial ECG was present in 73% of the patients (33% in anterior leads, 38% in inferior leads alone and 2% in both or other leads). Slightly more of the patients allocated captopril had evidence of inferior infarction but this excess was not statistically significant.
Following randomization, infarction was confirmed in 92% of the randomized patients. There were no significant differences in non-trial medications between the groups, except that antiarrhythmic drugs were used more often in the placebo group (16% captopril vs 30% placebo). None of these patients received any non-trial ACE inhibitor in hospital.
Ventricular arrhythmias
The overall prevalence of ventricular arrhythmias is shown in Table 2 . More than 10 ventricular ectopic beats/hour were observed in about 10-11% of patients, ventricular tachycardia in about 2-3% and complex ventricular arrhythmia in about 10-12%, with little difference between the prevalence at day 3 and that at day 14. The mean number of ventricular ectopic beats. h~' was significantly lower among those allocated captopnl, both at day 3 and at day 14 ( Table 3 , Fig. 1) .
The number of patients with frequent ventricular arrhythmias (defined as ventricular ectopic beats/hour >10) was also significantly lower at day 3 and at day 14 in the captopril group (Table 4, Fig. 2) . No Eur Heart J, Vol. 17, October 1996 significant differences in the incidence of ventricular tachycardia or of complex ventricular arrhythmias were demonstrated.
Discussion
The present study demonstrates that captopril starting from the first day of suspected myocardial infarction 
t is
See Table 2 for explanation of abbreviations. produces antiarrhythmic effects in both early and late phases of acute myocardial infarction. These results confirm the observation in our earlier small study 191 and are consistent with the trends in other studies 1 ' 0 " 12 '. Although one small study did not observe an antiarrhythmic effect of captopril on day 30 after myocardial infarction, treatment started 7 days after myocardial infarction in that study (and a significant reduction in ventricular arrhythmias was observed at 6 months). In GISSI-2 [I5) it was reported that >10 ventricular ectopic beats/hour was one of the strongest prognostic predictors in patients recovering from myocardial infarction following treatment with fibrinolytic agents. We found that captopril treatment led to a significant decrease in the number of patients with frequent ventricular ectopic beats. >10.h~'.
What mechanisms may be involved in the antiarrhythmic properties of ACE inhibitors? Experimental electrophysiological evidence of direct antiarrhythmic action by ACE inhibitors is controversial' ). ACE inhibitor therapy reduces angiotensin II production, and this results in decreased peripheral resistance, as well as a reduction in the load imposed on the heart, along with alleviation of sympathetic nervous strain' 16 ' 171 . ACE inhibitors also reduce the generation of aldosterone with subsequently diminished loss of magnesium and potassium and better preservation of electrolyte balance. Blockade of the toxic effects of angiotensin II on the myocardial cells may also be important.
In our study, antiarrhythmic drugs were more frequently used in the placebo group (30%) than in the captopril group (16%). The question arises as to whether this may have influenced the results. For example if these antiarrhythmic drugs produced proarrhythmic effects, increasing the number of ventricular ectopic beats, then this could bias the treatment comparisons. This seems unlikely, however, as all major trials with antiarrhythmics after myocardial infarction, including CAST 12 ' 271 , resulted in reductions in ventricular ectopic beats despite an increased mortality.
In conclusion, starting captopril early in acute myocardial infarction has an antiarrhythmic effect during the early (day 3) and late (day 14) phases of acute myocardial infarction. These antiarrhythmic properties have particular clinical relevance since in the post-CAST era we are fully aware of the proarrhythmic effects of classical antiarrhythmic drugs. ACE inhibitor therapy is devoid of the above adverse effects while still being able to stabilize cardiac rhythm. This antiarrhythmic effect of ACE inhibitor therapy may play a role, along with attenuation of remodelling, in reducing mortality when ACE inhibitors are used early in acute myocardial infarction (as in ISIS-4 [14] and in GISSI-3 [28] ) as well as long-term following myocardial infarction' 29 ' 301 .
